1. Home
  2. FULT vs BLLN Comparison

FULT vs BLLN Comparison

Compare FULT & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulton Financial Corporation

FULT

Fulton Financial Corporation

HOLD

Current Price

$22.17

Market Cap

3.5B

Sector

Finance

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$85.02

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FULT
BLLN
Founded
1882
2016
Country
United States
United States
Employees
3400
713
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FULT
BLLN
Price
$22.17
$85.02
Analyst Decision
Hold
Buy
Analyst Count
5
7
Target Price
$21.40
$126.71
AVG Volume (30 Days)
1.9M
360.5K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
3.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.39
$45.96
Revenue Next Year
$5.52
$30.11
P/E Ratio
$10.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.26
$61.96
52 Week High
$22.99
$138.70

Technical Indicators

Market Signals
Indicator
FULT
BLLN
Relative Strength Index (RSI) 67.76 56.31
Support Level $21.54 $79.33
Resistance Level $22.99 $98.48
Average True Range (ATR) 0.52 6.98
MACD 0.15 0.16
Stochastic Oscillator 90.06 60.08

Price Performance

Historical Comparison
FULT
BLLN

About FULT Fulton Financial Corporation

Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: